Basal-bolus insulin therapy in Type 1 diabetes: Comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin

Diabetic Medicine

Volumn 19, Issue 11, 2002, Pages 917-923

  Herz, M ^c,d   Arora, V ^c   Sun, B ^c   Ferguson, S C ^a   Bolli, G B ^b   Frier, B M ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF PERUGIA   (Italy)

^c ELI LILLY AND COMPANY   (United States)

^d LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Fixed insulin lispro mixtures; Hypoglycaemia; Insulin analogue; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN LISPRO; ISOPHANE INSULIN;

ADULT; ARTICLE; BODY WEIGHT; BOLUS INJECTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MEAL; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; BLOOD GLUCOSE; CIRCADIAN RHYTHM; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; PROTAMINES;

EID: 0036432961     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2002.00830.x     Document Type: Article

References (17)

1. Zinman B. The physiologic replacement of insulin: An elusive goal. N Engl J Med 1989; 321: 363-370.
2. Anderson JH Jr, Brunelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati Let al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 1997; 46: 265-270.
3. Home PD, Lindholm A, Riis A for European Insulin Aspart Study Group. Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: A randomized controlled trial. Diabet Med 2000; 17: 762-770.
4. Dimitriadis GD, Gerich JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983; 6: 374-377.
5. Jacobs MAJM, Keulen ETP, Kanc K, Casteleijn S, Scheffer P, Deville W et al. Metabolic efficacy of preprandial administration of Lys (B28), Pro (B29) human insulin analog in IDDM patients: A comparison with human regular insulin during a three-meal test period. Diabetes Care 1997; 20: 1279-1286.
6. Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P et al. Long-term intensive treatment of Type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999; 22: 468-477.
7. Del Sindaco P, Ciofetta M, Lalli C, Perriello G, Pampanelli S, Torlone E et al. Use of the short-acting insulin analog lispro in intensive treatment of IDDM: Importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med 1998; 15: 592-600.
8. Ferguson SC, Strachan MWJ, Frier BM. A comparative study of different insulin lispro and neutral protamine lispro fixed mixtures with Humulin M3: Effect on glycaemic control and hypoglycaemia (Abstract). Diabet Med 1998; 15 (Suppl. 1): S50.
9. Roach P, Trautmann M, Arora V, Sun B, Anderson JH. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro Mix25 and insulin lispro Mix50. Clin Ther 1999; 21: 523-534.
10. Koch GG. The use of nonparametric methods in statistical analysis of the two-period change-over design. Biometrics 1972; 8: 577-584.
11. Taulbee JD. A note on the use of nonparametric methods in the statistical analysis of the two-period changeover design. Biometrics 1982; 38: 1053-1055.
12. Grizzle JE. The two-period change-over design and its use in clinical trials. Biometrics 1965; 21: 467-480.
13. Jannson PA, Ebeling P, Smith U, Conget I, Coves MJ, Gomis R et al. Improved glycaemic control can be better maintained with insulin lispro than with human regular human insulin. Diab Nutr Metab 1998; 11: 194-199.
14. Ciofetta M, Lalli C, Del Sindaco P, Torlone E, Pampanelli S, Mauro L et al. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 1999; 22: 795-800.
15. Torlone E, Pampanelli S, Lalli C, Del Sindaco P, Di Vincenzo A, Rambotti AM et al. Effect of the short-acting insulin analog [Lys (B28), Pro (B29)] on postprandial blood glucose control in IDDM. Diabetes Care 1996; 19: 945-952.
16. Ebeling P, Jansson P-A, Smith U, Lalli C, Bolli GB, Koivisto VA. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin. Diabetes Care 1997; 20: 1287-1289.
17. Janssen MJM, Snoek FJ, Masurel N, Hoogma RPLM, Deville WL, Popp-Snijders Cet al. Optimized basal-bolus therapy using a fixed mixture of 75% lispro and 25% NPL insulin in type 1 diabetes patients. Diabetes Care 2000; 23: 629-633.